Shares of Biomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) have been given an average recommendation of "Buy" by the thirteen brokerages that are covering the company, MarketBeat reports. Two analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $39.36.
A number of equities research analysts recently weighed in on BMEA shares. D. Boral Capital reaffirmed a "buy" rating and set a $128.00 price objective on shares of Biomea Fusion in a research report on Friday, January 10th. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price objective on shares of Biomea Fusion in a research report on Tuesday, January 14th.
Read Our Latest Stock Report on BMEA
Biomea Fusion Stock Performance
Shares of Biomea Fusion stock traded up $0.15 during trading on Friday, reaching $2.91. The company had a trading volume of 615,018 shares, compared to its average volume of 970,640. The company has a market cap of $105.46 million, a price-to-earnings ratio of -0.73 and a beta of -0.34. The firm's fifty day moving average is $3.79 and its 200-day moving average is $6.55. Biomea Fusion has a fifty-two week low of $2.50 and a fifty-two week high of $18.40.
Institutional Trading of Biomea Fusion
A number of institutional investors have recently made changes to their positions in BMEA. Quest Partners LLC lifted its stake in shares of Biomea Fusion by 528.3% in the 3rd quarter. Quest Partners LLC now owns 19,553 shares of the company's stock worth $197,000 after acquiring an additional 16,441 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Biomea Fusion by 3.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 208,391 shares of the company's stock worth $2,105,000 after acquiring an additional 7,551 shares during the period. The Manufacturers Life Insurance Company acquired a new stake in shares of Biomea Fusion in the 3rd quarter worth approximately $111,000. FMR LLC lifted its stake in shares of Biomea Fusion by 0.7% in the 3rd quarter. FMR LLC now owns 5,431,525 shares of the company's stock worth $54,858,000 after acquiring an additional 39,959 shares during the period. Finally, Wexford Capital LP lifted its stake in shares of Biomea Fusion by 26.9% in the 3rd quarter. Wexford Capital LP now owns 130,336 shares of the company's stock worth $1,316,000 after acquiring an additional 27,619 shares during the period. 96.72% of the stock is owned by institutional investors and hedge funds.
Biomea Fusion Company Profile
(
Get Free ReportBiomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.
Featured Stories
Before you consider Biomea Fusion, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biomea Fusion wasn't on the list.
While Biomea Fusion currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
